Skip to content

Microdosing: all studies

Page 51 of 56: studies 501 to 510 of 555, newest first. Back to the microdosing overview

Research

From Mushrooms to Myolysis

The Journal of Nervous and Mental Disease July 29, 2022 Mariella Suleiman, Arnabh Basu, Sameen Belal et al. 8 citations

Abstract The involvement of certain recreational drugs, namely, hallucinogens, in the development of hyperactive syndromes is well known, but not well studied. In this report, we expand on this relationship by documenting the development of substance-induced psychosis in a young patient who used a large amount of psilocybin and developed symptoms of a first psychotic and manic episode,...

DOI: 10.1097/nmd.0000000000001489 (opens in new tab) Psilocybin Hallucinogen Psychosis Recreational drug +3

Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study

Psychiatry Research Case Reports July 15, 2022 Mika Turkia 14 citations

This article describes a case of a teenager with early complex trauma due to chronic domestic violence. Cannabis use triggered auditory hallucinations, after which the teenager was diagnosed with an acute schizophrenia-like psychotic disorder. Antipsychotic medication did not fully resolve symptoms. Eventually the teenager chose to self-medicate with LSD in order to resolve a suicidal...

DOI: 10.1016/j.psycr.2022.100029 (opens in new tab) Cannabis Psychosis Antipsychotic Schizophrenia object-oriented programming +2

Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.

British Journal of Pain July 14, 2022 Valerie Bonnelle, Will J Smith, Natasha L. Mason et al. 26 citations

Although several studies and reports have shown the potential analgesic use of serotonergic psychedelics in cancer pain, phantom limb pain and cluster headache, evidence supporting their use for chronic pain is still limited. The past years have seen a considerable renewal of interest toward the therapeutic use of these compounds for mood disorders, resulting in a marked increase in the number...

DOI: 10.1177/20494637221114962 (opens in new tab) Full text (opens in new tab) Psychedelics: classical psychedelics Hallucinogens Entheogens Psychotropics +9

Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow.

Psychopharmacology June 1, 2022 Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al. 22 citations

Stream of thought describes the nature of the mind when it is freely roaming, a mental state that is continuous and highly dynamic as in mind-wandering or free association. Classic serotonergic psychedelics are known to profoundly impact perception, cognition and language, yet their influence on the stream of thought remains largely unexplored. To elucidate the effects of LSD on the stream of...

DOI: 10.1007/s00213-021-06006-3 (opens in new tab) Full text (opens in new tab) LSD Abstract thinking Forward flow Free association +4

New Paradigms of Old Psychedelics in Schizophrenia

Pharmaceuticals May 23, 2022 Danish Mahmood, Sattam Khulaif Alenezi, Md Jamir Anwar et al. 29 citations

Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and behaviour. In recent years, there has been a surge in studies investigating these drugs because clinical studies have shown that these once banned drugs are well tolerated and efficacious in medically supervised low doses called microdosing....

Corrigendum to “Decreases in Suicidality Following Psychedelic Therapy

The Journal of Clinical Psychiatry May 9, 2022 Richard J. Zeifman, Dengdeng Yu, Nikhita Singhal et al. 2 citations correction

To the Editor: Our group recently published in JCP the first meta-analysis of patient-level data on the effects of psychedelics on suicidality. 1 While not described in our article, it is noteworthy that 2 suicidality-related events that had been deemed not attributable to the administration of a psychedelic (by the authors of the primary outcome studies) occurred within the studies included in...

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility.

European Neuropsychopharmacology May 1, 2022 Isabel Wießner, Rodolfo Olivieri, Marcelo Falchi et al. 42 citations

Psychedelics acutely impair cognitive functions, but these impairments decline with growing experiences with psychedelics and microdoses may even exert opposing effects. Given the recent evidence that psychedelics induce neuroplasticity, this explorative study aimed at investigating the potential of psychedelics to sub-acutely change cognition. For this, we applied a randomized, double-blind,...

DOI: 10.1016/j.euroneuro.2022.01.114 (opens in new tab) Full text (opens in new tab) Cognitive flexibility Executive functions Phonological verbal fluency Psycholytic dose +2

Psychedelic Cognition—The Unreached Frontier of Psychedelic Science

Frontiers in Neuroscience March 15, 2022 Maria Bălăeţ 28 citations

Psychedelic compounds hold the promise of changing the face of neuroscience and psychiatry as we know it. There have been numerous proposals to use them to treat a range of neuropsychiatric conditions such as depression, anxiety, addiction and PTSD; and trials to date have delivered positive results in favor of the novel therapeutics. Further to the medical use, the wider healthy population is...

Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain

Journal of Fungi March 11, 2022 Elaine Meade, Sarah Hehir, Neil J. Rowan et al. 24 citations

Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these...

Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.

Addiction Biology February 1, 2022 Harriet de Wit, Hanna Molla, Anya K. Bershad et al. 82 citations

The resurgence of interest in using psychedelic drugs, including lysergic acid diethylamide (LSD), in psychiatry has drawn attention to the medically unsupervised practice of 'microdosing'. Thousands of users claim that very low doses of LSD, taken at 3-4-day intervals, improve mood and cognitive function., However, few controlled studies have described the effects of the drug when taken in...

DOI: 10.1111/adb.13143 (opens in new tab) Full text (opens in new tab) LSD Microdosing Mood and cognition Clinical research